Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hovind

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Aging Clinical and Experimental Research|June 28, 2025
Compared to total serum testosterone, calculated free testosterone has a stronger association with lean mass, muscle strength, power, and physical function in older menKristian Villars Lolck, Julian Alcazar, Rikke Stefan Kamper, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 28, 2021
Associations between inflammatory markers, body composition, and physical function: the Copenhagen Sarcopenia StudyRikke S Kamper, Julian Alcazar, Lars L Andersen, et al.
Diabetes Care|March 29, 2003
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetesPeter Hovind, Lise Tarnow, Kasper Rossing, et al.
Diabetes|November 30, 2006
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudyFrederik Persson, Peter Rossing, Peter Hovind, et al.
Diabetes, Obesity & Metabolism|October 19, 2016
The effect of liraglutide on renal function: A randomized clinical trialBernt J von Scholten, Frederik Persson, Signe Rosenlund, et al.
Kidney International|June 12, 2014
Improved prognosis of diabetic nephropathy in type 1 diabetesGudbjörg Andrésdóttir, Majken L Jensen, Bendix Carstensen, et al.
Seminars in Nephrology|March 16, 2004
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsHans-Henrik Parving, Steen Andersen, Peter Jacobsen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|July 9, 2008
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) studyFrederik Persson, Peter Rossing, Peter Hovind, et al.
Ugeskrift for Laeger|January 29, 2005
[Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication]Peter Hovind, Lise Tarnow, Peter Rossing, et al.
Diabetes Care|December 24, 2005
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathyTri Q Nguyen, Lise Tarnow, Steen Andersen, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Aging Clinical and Experimental Research|June 28, 2025
Compared to total serum testosterone, calculated free testosterone has a stronger association with lean mass, muscle strength, power, and physical function in older menKristian Villars Lolck, Julian Alcazar, Rikke Stefan Kamper, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 28, 2021
Associations between inflammatory markers, body composition, and physical function: the Copenhagen Sarcopenia StudyRikke S Kamper, Julian Alcazar, Lars L Andersen, et al.
Diabetes Care|March 29, 2003
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetesPeter Hovind, Lise Tarnow, Kasper Rossing, et al.
Diabetes|November 30, 2006
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudyFrederik Persson, Peter Rossing, Peter Hovind, et al.
Diabetes, Obesity & Metabolism|October 19, 2016
The effect of liraglutide on renal function: A randomized clinical trialBernt J von Scholten, Frederik Persson, Signe Rosenlund, et al.
Kidney International|June 12, 2014
Improved prognosis of diabetic nephropathy in type 1 diabetesGudbjörg Andrésdóttir, Majken L Jensen, Bendix Carstensen, et al.
Seminars in Nephrology|March 16, 2004
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsHans-Henrik Parving, Steen Andersen, Peter Jacobsen, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|July 9, 2008
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) studyFrederik Persson, Peter Rossing, Peter Hovind, et al.
Ugeskrift for Laeger|January 29, 2005
[Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication]Peter Hovind, Lise Tarnow, Peter Rossing, et al.
Diabetes Care|December 24, 2005
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathyTri Q Nguyen, Lise Tarnow, Steen Andersen, et al.
Pageof 6